---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280660566.md"
description: "CollPlant Biotechnologies shares are trading lower after the company reported worse-than-expected Q4 financial results."
datetime: "2026-03-26T15:34:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280660566.md)
  - [en](https://longbridge.com/en/news/280660566.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280660566.md)
---

# 

CollPlant Biotechnologies shares are trading lower after the company reported worse-than-expected Q4 financial results.

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [CLGN.US](https://longbridge.com/en/quote/CLGN.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)